Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Unknown 7Completed 7Terminated 4Recruiting 4Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 26Myelodysplastic Syndromes 13Recurrence 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Chronic 4Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Primary Myelofibrosis 1Polycythemia Vera 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myeloid Malignancies 1Myelodysplastic-Myeloproliferative Diseases 1Lymphodepleting Chemotherapy 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Hypomethylating Agent 1Human Papillomavirus-Negative Neck Squamous Cell Carcinoma 1Hodgkin Disease 1Hematologic Neoplasms 1Congenital Bone Marrow Failure Syndromes 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1Accelerated Phase Myeloproliferative Neoplasm 1

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Decitabine × Clear all
NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Chinese PLA General Hospital

Phase 1/2 Recruiting
250 enrolled

Neoplasms, Recurrence

NCT06686108 2025-05-07

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
59 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06316960 2024-08-22

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Children's Hospital of Soochow University

Phase 2 Recruiting
50 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Loyola University

Phase 2 Recruiting
40 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡